VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PRE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
PREPrenetics Global Limited
$18.58$316M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksPREBalance Sheet

Prenetics Global Limited (PRE) Balance Sheet

7Y historyFree accessUpdated daily

The company's balance sheet reflects significant volatility, with total assets contracting from $254.2M in 2023Q4 to $175.3M in 2026Q1 alongside a major goodwill impairment.

PRE Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Total Current Assets132.11M83.39M86.15M93.66M241.81M106.89M43.96M15.63M
Cash & Short-Term Investments106.03M61.49M62.81M72.74M184.12M45.19M14.8M11.82M
Cash Only56.02M32.13M52.25M45.71M146.66M35.29M14.49M11.52M
Short-Term Investments50.02M29.36M10.56M27.03M37.46M9.91M314.71K294.06K
Accounts Receivable11.88M2.98M5.61M5.29M42.5M47.05M23.1M2.89M
Days Sales Outstanding21.3911.7866.8188.871.18K1.37K129.34114.34
Inventory14.2M7.06M6.57M3.13M4.53M6.83M4.5M547.85K
Days Inventory Outstanding59.4659.07157.4588.39173.36279.1342.2730.68
Other Current Assets011.86M3.55M8.31M4.58M7.31M979.6K374.36K
Total Non-Current Assets43.19M120.13M127.43M160.51M70.32M41.61M34.93M14.06M
Property, Plant & Equipment594K1.76M7.81M5.78M13.1M13.04M4.69M2.11M
Fixed Asset Turnover62.22x52.40x3.92x3.76x1.00x0.96x13.89x4.37x
Goodwill0037.36M29.17M33.8M3.98M3.99M3.85M
Intangible Assets40K44.7M11.57M13.43M14.79M23.83M23.96M6.27M
Long-Term Investments204.5M67M69.33M107.84M788.47K001.66M
Other Non-Current Assets40.22M6.68M1.35M4.27M7.6M693.55K2.28M161K
Total Assets175.3M203.52M213.57M254.17M312.13M148.51M78.88M29.69M
Asset Turnover0.59x0.45x0.14x0.09x0.04x0.08x0.83x0.31x
Asset Growth %-50.09%-4.71%-15.97%-18.57%110.18%88.26%165.72%-
Total Current Liabilities25.64M27.67M36.55M39.48M57.2M58.74M47.07M11.9M
Accounts Payable1.96M7.72M3.67M1.67M7.29M9.98M13.44M2.76M
Days Payables Outstanding39.5864.6787.9647.23278.78407.9126.29154.61
Short-Term Debt01.33M0001.67M15.47M0
Deferred Revenue (Current)19.86M3.09M6.49M6.11M5.67M9.59M00
Other Current Liabilities015.5M15.07M15.49M17.47M22.64M10.92M7.79M
Current Ratio5.15x3.01x2.36x2.37x4.23x1.82x0.93x1.31x
Quick Ratio4.60x2.76x2.18x2.29x4.15x1.70x0.84x1.27x
Cash Conversion Cycle41.276.18136.31130.031.07K1.24K45.32-9.6
Total Non-Current Liabilities28.64M1.34M5.68M4.53M11.47M490.66M804.57K930.56K
Long-Term Debt0437K000486.4M0124.32K
Capital Lease Obligations2.21M437K3.01M867K3.76M3.6M804.57K775.23K
Deferred Tax Liabilities26K8K2.17M2.62M3.19M659.5K00
Other Non-Current Liabilities28.58M460K499K1.05M4.52M0031.01K
Total Liabilities54.28M29.01M42.23M44.01M68.67M549.4M47.88M12.83M
Total Debt457K2.2M5.77M2.37M6.65M491.67M17.14M1.46M
Net Debt-55.56M-29.93M-46.48M-43.34M-140.01M456.38M2.65M-10.07M
Debt / Equity0.00x0.01x0.03x0.01x0.03x-0.55x0.09x
Debt / EBITDA-0.01x-----11.98x-
Net Debt / EBITDA1.55x-----1.86x-
Interest Coverage-319.79x-149.26x-283.25x-465.40x-932.14x-5127.08x-64.50x-299.80x
Total Equity121.02M174.51M171.35M210.16M243.46M-400.89M31.01M16.85M
Equity Growth %-54.53%1.85%-18.47%-13.68%160.73%-1392.92%83.99%-
Book Value per Share7.1312.4213.4918.6948.03-108.374.192.28
Total Shareholders' Equity121.11M174.6M170.39M206.36M237.06M-400.81M31.08M16.91M
Common Stock25K25K19K18K13.7K1.49K15.35M45.69M
Retained Earnings00-517.07M-470.77M-408.04M0-43.58M-41.64M
Treasury Stock00-639K-62K-661.52K000
Accumulated OCI121.09M0-169.25M-176.03M-185.69M-400.81M21.42M12.86M
Minority Interest-93K-93K957K3.8M6.4M-84.97K-77.41K-53.21K

Key Metrics

Growth RegimeAccelerating
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Rapid cash reserve depletion

Asset Base Contraction Amidst Volatility

According to recent financial filings, Prenetics' total assets declined from $254.2M in 2023Q4 to $175.3M by 2026Q1, reflecting a significant reduction in the company's balance sheet scale as it pivots away from pandemic-era operations toward a more specialized, albeit smaller, clinical diagnostic footprint.

The consistent downward trend in total assets suggests that the company is shedding non-core assets or experiencing a natural decay in pandemic-related infrastructure. Investors should monitor whether this contraction represents a strategic streamlining or a loss of competitive scale in the highly fragmented Asian diagnostic market.

Liquidity Buffer Under Increasing Pressure

As reported in quarterly statements, Prenetics' cash position fluctuated significantly, dropping to $32.1M in 2025Q4 before recovering to $56.0M in 2026Q1, yet this volatility highlights a precarious reliance on external financing to maintain operations while the company continues to burn through its available capital reserves.

While the current ratio of 5.15 in 2026Q1 appears robust on the surface, it is heavily influenced by the timing of cash inflows and does not account for the underlying structural cash burn. The lack of consistent liquidity growth suggests that the company remains vulnerable to sudden shocks in its operating environment.

Asset Composition Reflects Strategic Pivot

Based on the provided balance sheet data, goodwill has experienced significant volatility, peaking at $44.7M in 2025Q4 before dropping to $40.0K in 2026Q1, which suggests a major impairment or restructuring event that warrants further investigation into the quality of the company's historical acquisitions.

The rapid fluctuation in intangible assets indicates that the company's valuation of its acquired businesses is highly sensitive to changing market conditions. This volatility may imply that the firm's long-term strategic investments are not yet yielding the stable, tangible returns necessary to anchor the balance sheet.

Hidden Risks in Equity Structure

As indicated by the financial statements, the company reported zero retained earnings for most of the observed periods, masking the cumulative impact of historical losses that were previously highlighted by a $517.1M deficit in 2024Q4, which suggests a potential accounting reset or reorganization of the equity base.

The absence of retained earnings in recent quarters may obscure the true extent of the company's historical value destruction. Investors should be wary of whether this presentation effectively hides the ongoing impact of persistent operating losses on the company's long-term equity value.

PRE — Frequently Asked Questions

Quick answers to the most common questions about buying PRE stock.

What are the total assets of Prenetics Global Limited (PRE)?

As of 2025, Prenetics Global Limited (PRE) had total assets of $203.5M including $83.4M in current assets.

How much debt does Prenetics Global Limited (PRE) have?

Prenetics Global Limited (PRE) carries total debt of $2.2M, offset by $61.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Prenetics Global Limited?

Prenetics Global Limited (PRE) has total shareholders' equity (book value) of $174.6M ($12.42 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Prenetics Global Limited's current ratio and liquidity?

Prenetics Global Limited (PRE) reported a current ratio of 3.01x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.